Xanthus' Symadex(TM) Remyelination

Xanthus' Symadex Can Reverse Disease in Preclinical Multiple ...
PR Newswire (press release) - New York,NY,USA
... disease and that it can permit nerve remyelination. ... Alfred Ajami, PhD, Chief Scientific Officer at Xanthus. About Symadex(TM) Symadex (formerly C-1311) is the ...

---

fingolimod

New data for FTY720 - aiming to become the first orally effective ...
PipelineReview.com (press release) - Barcelona,Spain
BASEL, Switzerland | Sep 28, 2006 | The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering ...

---

fampridine acorda

Hot stocks of the week: Acorda, AnorMED
BusinessWeek - USA
SEP. 29 5:10 PM ET In a week that saw the Dow briefly hit a record high, shares of Acorda Therapeutics Inc. shares of a drug developer ...

---

FTY720

New Data for FTY720 -- Aiming to Become the First Orally Effective ...
PR Newswire (press release) - New York,NY,USA
... II results show sustained reduction in relapses and inflammation in MS patients, with low disease activity maintained over two years * FTY720 may represent a ...

Market Report -- In Play (NVS)
MSN Money - USA
New data for FTY720 - aiming to become the first orally effective MS treatment - show sustained benefits over two years The developmental oral therapy FTY720 ...

---

Tysabri

Biogen/Elan: MS Drug Tysabri Reduces Cognitive Disfunction
Easy Bourse (Communiqués de presse) - Paris,France
(ELN) said a Phase III study showed the multiple-sclerosis drug Tysabri reduced the proportion of patients with worsening cognitive function. ...

New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate ...
Canada NewsWire (press release) - Canada
... Elan Corporation, plc (NYSE: ELN) announced today that data from the Phase III AFFIRM monotherapy study demonstrated that treatment with TYSABRI(R) (natalizumab ...

Biogen Idec, Elan release positive phase III data on TYSABRI for ...
Forbes - USA
... AFX) - Biogen Idec and Elan Corporation PLC said data from their Phase III AFFIRM monotherapy study show treatment with their TYSABRI drug significantly ...

Presentatie nieuwe data aangaande TYSABRI op ECTRIMS congres laat ...
Netherlands Corporate News (persbericht) - Netherlands
( BW)(BIOGEN/ELAN)(BIIB)(ELN) New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with ...

Biogen, Elan unveil new Tysabri data
Eyewitness News - East Providence,RI,USA
NEW YORK Drug developers Biogen Idec and Elan Corporation say data from a late-stage study of Tysabri (ty-SAH'-bree) shows it's effective in reducing cognitive ...

Biogen, Elan say Tysabri results positive
Bizjournals.com - Charlotte,NC,USA
... said Thursday that data from a late-stage study of Tysabri showed it was effective in reducing cognitive degeneration in multiple sclerosis patients. ...
See all stories on this topic

MS drug Tysabri helps cognition
United Press International - USA
28 (UPI) -- US firm Biogen Idec and Irish firm Elan said Thursday new data show multiple-sclerosis drug Tysabri helps cognitive ability in MS. ...